Next Article in Journal
Integrating Full-Length and Second-Generation Transcriptomics to Reveal Differentially Expressed Genes Associated with the Development of Corydalis yanhusuo Tuber
Previous Article in Journal
The Feasibility of Less-Invasive Bentall Surgery: A Real-World Analysis
Previous Article in Special Issue
Performance of Deep-Learning Solutions on Lung Nodule Malignancy Classification: A Systematic Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 13
Issue 11
10.3390/life13112206
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Helicobacter pylori (H. pylori) Infection-Associated Dyslipidemia in the Asir Region of Saudi Arabia

by
Mohammad Asrar Izhari
1,*,
Omar A. Al Mutawa
1,
Ali Mahzari
1,
Essa Ajmi Alotaibi
2,
Maher A. Almashary
3,
Jaber Abdullah Alshahrani
4,
Ahmed R. A. Gosady
5,
Abdulrahman M Almutairi
6,
Daifallah M. M. Dardari
7 and
Abdul Kareem A. AlGarni
8
1
Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Al-Baha University, Al Baha 65522, Saudi Arabia
2
Department of Dermatology, Al-Kharj Military Hospital, Al-Kharj 11361, Saudi Arabia
3
Medical Services Department, Armed Forces Medical Services, Riyadh 11159, Saudi Arabia
4
Department of Medical Training and Education, Armed Forces Hospital Southern Region, Khamis Mushait 62413, Saudi Arabia
5
Laboratory Department, Baish Primary Healthcare, Jazan 87311, Saudi Arabia
6
Health facilities Infection Control Department, General Directorate of Health, Al-Baha 11134, Saudi Arabia
7
Laboratory Department, Baish General Hospital, Jazan 87732, Saudi Arabia
8
Department of Hematology, King Saud Bin Abdulaziz University for Health Sciences, Al-Ahsa 11451, Saudi Arabia
*
Author to whom correspondence should be addressed.
Life 2023, 13(11), 2206; https://doi.org/10.3390/life13112206
Submission received: 14 October 2023 / Revised: 10 November 2023 / Accepted: 10 November 2023 / Published: 13 November 2023
(This article belongs to the Special Issue Emerging Risk Factors Associated with Public Health)
Browse Figures
Versions Notes

Abstract

:
Objectives: H. pylori-associated dyslipidemia has been reported to be a major risk factor for atherosclerosis and coronary heart diseases. We aimed to investigate the association of the H. pylori infection with dyslipidemia. Methods: A retrospective case–control study was undertaken to evaluate H. pylori-associated dyslipidemia, where H. pylori-positive individuals were treated as the case group (n = 260) while H. pylori-negative individuals were considered as the control group (n = 250). The mean ± SD of the age of the patients included (n = 510) was 44.01 ± 13.58 years. Study subjects with a total cholesterol level of >5.17 mmol/L and/or a triglyceride level of >1.69 mmol/L and/or an LDL-C level of >2.59 mmol/L and/or an HDL-C level of <1 mmol/L in males and/or an HDL-C level of <1.3 mmol/L in females were defined as dyslipidemia. Descriptive (mean, standard deviation, median, and IQR) and inferential (t-test, chi-square test, and logistic regression) statistical analyses were undertaken using the R-base/R-studio (v-4.0.2)/tidyverse package. Univariate and bivariate logistic regressions were executed to calculate the crude and adjusted odds ratio along with the p-value. A p-value of <0.05 was the cut-off for statistical significance. We used ggplot2 for data visualization. Results: The differences in overall mean ± SD (H. pylori positive vs. negative) of the cholesterol (5.22 ± 1.0 vs. 5.49 ± 0.85, p < 0.01), triglyceride (1.66 ± 0.75 vs. 1.29 ± 0.71, p < 0.001), LDL-C (3.43 ± 0.74 vs. 3.26 ± 0.81, p < 0.05), and HDL-C (1.15 ± 0.30 vs. 1.30 ± 0.25, p < 0.001) levels were statistically significant. The cholesterol and LDL-C levels in ages >60, age = 30–60, in females, and LDL-C levels in males were not significantly different for the H. pylori-positive and -negative groups. The proportion (H. pylori positive vs. negative) of hypercholesterolemia (190/59.9% vs. 127/40% p < 0.01), hypertriglyceridemia (136/68% vs. 64/32% p < 0.001), high LDL-cholesterolemia levels (234/53% vs. 201/46% p < 0.01), and low HDL-cholesterolemia levels (149/71% vs. 60/28.7% p < 0.01) were statistically significant. The odds of having hypercholesterolemia (AOR: 2.64, 95%CI: 1.824–3.848, p < 0.001), hypertriglyceridemia (AOR: 3.24, 95%CI: 2.227–4.757, p < 0.001), an increased LDL-C level (AOR: 2.174, 95%CI: 1.309–3.684, p < 0.01), and a decreased HDL-C level (AOR: 4.2, 95%CI: 2.937–6.321, p < 0.001) were 2.64, 3.24, 2.17, and 4.2 times higher in the H. pylori-infected individuals as compared with the H. pylori-uninfected group. Conclusion: Our results demonstrate that an enhanced risk of dyslipidemia is associated with the H. pylori infection, which can aggrandize the atherosclerosis process. The evaluation of temporal variation in the lipid profile in H. pylori-infected individuals is recommended for the effective management of H. pylori-infected patients.

1. Introduction

H. pylori (spiral-shaped, microaerophilic Gram-negative bacteria) [1] causes widespread infection in almost half (50%) of the global population [2]. Although the prevalence of H. pylori infection is ubiquitous, high geographic variability has been reported [3]. The prevalence of H. pylori infection among adults in different geographical regions of Saudi Arabia ranges from 28–46% while 40% has been documented in children [4]. Moreover, the highest prevalence has been reported in the southern region of Saudi Arabia [5]. H. pylori infection is in a hyper-endemic state in Saudi Arabia and it affects all age groups [6]. In the majority of the cases, the individual remains asymptomatic for a longer period, fostering a prolonged colonization and debilitation of gastric mucosa [7] that triggers the development of various diseases in the gastrointestinal tract [8].
Predominantly, H. pylori causes chronic gastritis, peptic ulcers [9], gastric carcinogenesis [10], as it is considered a class 1 carcinogen, and antrum gastritis [11]. In addition to this, the International Agency for Research on Cancer (IARC) has identified H. pylori as a class 1 carcinogen [12]. In recent years, the implication of H. pylori infection in extra-gastric clinical manifestations such as IDA [13], immune thrombocytopenia [14] dyslipidemia [15], atherosclerosis, cardiovascular disease, neurological disorders, dermatological diseases, and ophthalmic and metabolic diseases [2] have been reported.
An avalanche of epidemiological studies and clinical reports has delineated the significant association of H. pylori with risk factors for cardiovascular diseases [16,17]. A very recently published observational cohort meta-analysis report by Sun et al. has demonstrated the increased risk of developing CVD in H. pylori-infected patients [18]. However, the association was not confirmed in various epidemiological investigations [19,20], and the association of H. pylori with the risk of enhanced cardiovascular disease is not fully understood and remains controversial [18]. The human microbiome plays a key role in lipid metabolism and is closely related to dyslipidemia [21]. Plasma lipid and lipoprotein abnormality constitute dyslipidemia and are metabolically interrelated [22]. The H. pylori-triggered inflammatory response alters the nutrient absorption and serum lipid profile [23]. The intestinal absorption of these factors is crucial to maintain their optimum level in the body [24]. Low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein (HDL), triglycerides, and cholesterol together constitute the serum lipid profile [25]. Dyslipidemia is one of the well-known risk factors for coronary heart disease and heart stroke [26]. An elevation in any of the lipid profiles, for instance triglycerides (TGs), total cholesterol (TC), and low density lipoprotein cholesterol (LDL-C) or a drop in the level of high density lipoprotein cholesterol (HDL-C), is termed as dyslipidemia (hyper-dyslipidemia and hypo-dyslipidemia) [27] which may contribute to atherosclerosis and cardiovascular diseases (CVDs) [2,28]. Dyslipidemia has been reported to be one of the most crucial risk factors for CVDs [29]. Atherogenic dyslipidemia is an important risk factor for myocardial infarction which may lead to a stroke [30].
The determination of the lipid profile is necessary for the diagnosis and management of dyslipidemia, atherosclerosis risk, and cardiovascular diseases [31]. Hypercholesterolemia brings about 33% of the global ischemic heart diseases that lead to an estimated 2.6 million deaths worldwide [15]. The implication of H. pylori infection in the alteration of the serum lipid profile has been reported. Gastric colonization and invasion by H. pylori trigger disturbances in the lipid profile as a result of impaired coagulation cascade activation, autoimmunity due to antigenic molecular mimicry between human epitopes and that of H. pylori, the impairment of nutritional absorption, and an inflammatory response to the infection [32,33]. A thorough investigation of the association of H. pylori-associated dyslipidemia is worthy of being addressed to lay down the policy for the effective management of H. pylori-infected patients. Therefore, the current study aimed to assess the association of H. pylori infections with dyslipidemia in a population of the Asir region of the Kingdom of Saudi Arabia.

2. Methods and Materials

2.1. Data acquisition, Study Area, Design, Population, and Period

An observational study design (hospital-dependent comparative case-control study) was adopted in the current study to evaluate the extra-gastric impact of H. pylori in a population of the Asir region of the Kingdom of Saudi Arabia. Laboratory investigation reports of H. pylori-infected patients and H. pylori-negative cases available at Armed Forces Hospitals of the southern (Asir) region of Saudi Arabia for approximately six years (1 June 2017 to 27 March 2023) were thoroughly examined, reviewed, and screened for demographic, CBC, lipid profile, ferritin, and other metabolic parameter data. Relevant data were plugged into MS Office 365 (an Excel sheet) for cleaning, stratification, and processing. Medical records of all the hospitals of the Asir region, namely, the King Fahad Military Hospital (Khamis Mushait), King Faisal Military Hospital (Military City, Khamis Mushait), Family & Community Medical Center Asir Base, (Khamis Mushait), Family & Community Medical Center Aba (Abha City), and Family & Community Medical Center Ahad Rafidah, (Ahad Rafidah province) were included in this study for data mining.

2.2. Eligibility (Inclusion) Criteria

H. pylori-infected patients and the H. pylori-negative cases of males, females, and all age groups were included in this study.

2.3. Eligibility (Exclusion) Criteria

For excluding participants from this study, historical background, clinical condition, therapeutic, and laboratory records present in the hospitals were examined critically. Based on body mass index (BMI), the A hemoglobin A1C (HbA1C) cut off laid down by the ministry of health, Saudi Arabia for obesity and diabetes (HbA1C ≥ 6.5%) patients were excluded. Following the examination of therapeutic records of the hospital patients on lipid-lowering medications, antiviral treatment was excluded. Participants with tuberculosis, hypertension (blood pressure exceeding 130/80 mm of Hg), kidney transplants, and pregnant women as well as those severely sick with multiple comorbidities (Hemodialysis and intensive care unit patients: admitted patients with obesity, hepatopathy, nephropathy, and H. pylori-infected gastric cancer patients that were kept on the prolonged use of a proton pump inhibitor as well as patients on corticosteroid therapy) were excluded by inquisitively examining their clinical records to maintain the homogeneity of the participants and the internal validity and generalizability of the findings of this study. The use of corticosteroid, proton pump inhibitors and other medicines was assessed by a robust system of the drug and therapeutic committee (DTC), in collaboration with pharmacists and physicians at the hospital to ensure drug safety and rational drug use based on the patients’ physiological conditions. Corticosteroid and PPIs are lipid-interfering drugs, and their prolonged use could be one of the confounding factors in this study; therefore, such participants were excluded from this study, and the assessment of prolonged use was accomplished by DTC.

2.4. Determination of Sample Size

The sample size for this study was determined by applying the standard statistical equation n = N/(1 + Ne2). A 95% confidence level and a margin of error of 0.05 was taken into consideration for the determination of sample size [34]. A sample size of approximately n = 400 was determined appropriate for this study based on the standard statistical equation n = N/(1 + Ne2) used. A total of n = 923 hospital records were reviewed and examined thoroughly, and n = 413 were excluded from this study as they did not meet the inclusion criteria. In the current study, a sample size of n = 510 was taken into consideration to compensate for the sampling variability (Figure 1).

2.5. Operational/Case Definition

Dyslipidemia was characterized when the total cholesterol level was >5.17 mmol/L and/or the triglyceride level was >1.69 mmol/L and/or the LDL-C level was >2.59 mmol/L and/or the HDL-C level was <1 mmol/L in males and/or the HDL-C level was <1.3 mmol/L in females [23,35].

2.6. Data Generation and Laboratory Techniques

Demographic data (gender and age in years) of all the study participants were obtained from the medical records of all the hospitals included in this study. Primarily, fasting blood specimens and stool specimens were collected at the respective laboratory collection centers of all the hospitals included in this study by applying standard collection procedures, as per the standard operating procedures (SOPs) of the hospitals. The stool specimens were collected aseptically in sterile collection containers. Blood was further processed to separate serum by centrifugation for analysis. Liver function tests (LFTs) and the lipid profile, HDL-C, LDL-C, TG, and TC, were measured by the D×C 700 AU auto-analyzer (Beckman Coulter, Brea, CA, USA) by using commercially available kits [36]. AU is a recent variant with combined hardware- and software-integrated characteristics. Software-based validation is automated by the execution of an analytical measurement range (AMR) and/or linearity along with intra-run and inter-run precision/accuracy checks, the verification of sensitivity (low detection limit), carryover acceptability, and a reference range [36]. All the test specimens were processed as per the manufacturer’s instructions and laboratory standard procedures. Before processing the test samples, the analyzer had to pass the system setup, calibration module, and quality control (QC) testing with positive and negative controls to obtain the validated results of the parameters assessed. Meanwhile, for measuring the complete blood count (CBC), the ADVIA 2120i hematology system was used. Ferritin was determined by applying the D × I 800 auto-analyzer (Beckman Coulter, Brea, CA, USA). Quality control was maintained as per the manufacturer’s instructions prior to testing each specimen.
The exposure was ascertained by using the sole method of diagnosis of H. pylori infection based on the detection of H. pylori antigens in the stool samples of the participants, which was termed as the stool antigen tests (SATs). SATs are non-invasive modules for the diagnosis of H. pylori infection, as per both European and Japanese guidelines [37]. For the detection of the antigen H. pylori in stool specimens, the rapid immune-chromatographic test was undertaken using the Immuno CARD STAT (Meridian Bioscience. Inc., Cincinnati, OH, USA), HPSA ztest procedure. The stool specimens were diluted with a sample diluent and applied to the test device. The loaded test device was incubated at 20–26 degrees Celsius for five minutes. The results of the samples along with those of the positive and negative controls were recorded and interpreted. The test card contains in-built positive and negative controls to validate the results of antigen detection in stool samples for the primary diagnosis of H. pylori infection [37].

2.7. Data Quality Assurance and Management

The data collector/investigator was trained to identify and remove any technical biases. Multiple reviews were carried out to ensure the completeness of the demographic and laboratory data. Discrepant and/or incomplete data were eliminated from this study.

2.8. Statistical Analysis of Data and Interpretation

Data were stratified by gender and age categories (age < 30 years, age = 30–60 years, and age > 60 years) before the data analysis. H. pylori antigen-positive participants were considered as a case while antigen-negative participants were treated as a control group. Descriptive data analysis was undertaken by applying R-base/R-studio (v-4.0.2) and an Ubuntu/Linux-based machine to measure the mean, median, and interquartile range (IQR) of all the stratified groups in the case of continuous variables, which were summarized in a table. Results retrieved from the analysis of categorical variables were summarized as frequency and proportion/percentage. Using the R-base/R-studio (v-4.0.2)/tidyverse package, inferential statistical analyses (t-test, chi-square test, univariate, and multivariate logistic regressions) were accomplished. p-values of <0.05 were considered as cut-off values for statistical significance. For data visualization, we used different packages of R, such as ggplot2.

3. Results

3.1. Baseline Characteristics (Demographic and Lipid Profile) of the Study Participants

The data retrieved for all the participants (n = 510) were stratified into six categories (two categories by gender, three categories by age, and one overall category). Following stratification, descriptive statistical analyses were accomplished on the demographic, lipid profile (cholesterol, triglyceride, LDL-C, and HDL-C), liver function test (LFT), and HbA1c data for all the six categories to determine the mean, median, standard deviation (SD), and interquartile range to represent the shape and characteristics of the overall data included in this study, which have been tabulated systematically in Table 1. The mean ± SD age for the overall, male, and female categories were 44.01 ± 13.58, 43.31 ± 13.81, and 44.69 ± 13.33, respectively. The mean ± SD cholesterol levels of the overall, male, and female categories and for ages < 30, age = 30–60, and ages > 60 were found to be 5.36 ± 0.96, 5.38 ± 1.02, 5.34 ± 0.92, 4.78 ± 0.89, 5.47 ± 0.93, and 5.38 ± 1.05, respectively. The mean ± SD triglyceride levels of the overall, male, and female categories and for ages < 30, age = 30–60, and ages > 60 were considered to be 1.49 ± 0.72, 1.60 ± 0.74, 1.37 ± 0.68, 1.18 ± 0.65, 1.52 ± 0.73, and 1.20 ± 0.66, correspondingly. The mean ± SD HDL-C and LDL-C levels for the overall, male, and female categories and for ages < 30, age = 30–60, and ages > 60 were 1.23 ± 0.29, 1.11 ± 0.26, 1.35 ± 0.27, 1.27 ± 0.31, 1.23 ± 0.28, 1.20 ± 0.31 and 3.35 ± 0.78, 3.43 ± 0.84, 3.27 ± 0.71, 2.82 ± 0.66, 3.45 ± 0.77, 3.35 ± 0.79, respectively (Table 1). The mean ± SD ALT, AST, ALP, and HbA1c levels as well as the median (IQR) cholesterol, triglyceride, LDL-C, HDL-C, ALT, AST, ALP, and HbA1c levels for all six data categories are tabulated in Table 1.

3.2. Comparative Status of Lipid Profile among All the Participants (n = 510)

The mean ± SD cholesterol, triglyceride, LDL-C, and HDL-C levels of the two groups (H. pylori-positive and H. pylori-negative participants) were compared to assess statistically significant differences by the H. pylori-infection status for all the six data categories. The levels of cholesterol (mean ± SD; 5.49 ± 0.85, 95%CI; 0.10–0.44), triglycerides (mean ± SD; 1.66 ± 0.75, 95%CI; 0.24–0.48), LDL-C (mean ± SD; 3.43 ± 0.74, 95%CI; 0.02–0.30), and HDL-C (mean ± SD; 1.15 ± 0.30, 95%CI; 0.10– 0.20) were measured in the H. pylori-positive participants for the overall categories. On the other hand, the levels of cholesterol (mean ± SD; 5.22 ± 1.0, 95%CI; 0.10–0.44), triglycerides (mean ± SD; 1.29 ± 0.62, 95%CI; 0.24–0.48), LDL-C (mean ± SD; 3.26 ± 0.81, 95%CI; 0.02–0.30), and HDL-C (mean ± SD; 1.30 ± 0.25, 95%CI; 0.10–0.20) were measured in the H. pylori-negative participants for the overall categories (Table 2). A statistically significant difference in the cholesterol (p < 0.01), triglyceride (p < 0.001), LDL-C (p < 0.05), and HDL-C (p < 0.001) levels was observed for the overall study participants. The differences in the mean ± SD LDL-C of the H. pylori-positive and H. pylori-negative participants (p > 0.05) in the male, female, age = 30–60, and age > 60 categories were not statistically significant. The differences in the mean ± SD cholesterol levels of the H. pylori-positive and H. pylori-negative participants (p > 0.05) in the female, age = 30–60, and age > 60 categories were not statistically significant. A significant difference was observed for the HDL-C levels (p < 0.001) across all the data categories. The comparative mean ± SD and p-values for all the four components of the lipid profile in the H. pylori-positive and -negative participants are summarized in detail in Table 2. The mean ± SD and 95%CI for each laboratory parameter of the lipid profile by H. pylori infection of all the six data categories are tabulated (Table 2). The median (IQR) cholesterol levels (Figure 2a), triglyceride levels (Figure 2b), LDL-C levels (Figure 2c), and HDL-C levels (Figure 2d) by H. pylori-infection status are illustrated in Figure 2. The correlation matrix between each component of the lipid profile and its distribution by H. pylori-infection status are depicted in Figure 3. A strong positive correlation was measured between the cholesterol and LDL levels in both the H. pylori-infected (r = 0.872, p < 0.001) and -uninfected participants (r = 0.959, p < 0.001) (Figure 3). A weak negative correlation was observed between the triglyceride and HDL levels in the H. pylori-positive participants (r = −0.447, p < 0.001). A comparatively weak negative correlation (r = −0.016, p > 0.05) was recorded between the HDL and LDL levels in the H. pylori-positive case (Figure 3).

3.3. The Magnitude of Imbalance in Lipid Profile among n = 510 Study Participants

By applying a two-sample test, the equality of proportion and the difference in the proportions of the infected individuals with altered lipid profiles and non-infected individuals with disturbed serum lipid profiles were calculated (Table 3). A statistically significant difference (p < 0.001) was observed among the overall proportion of hypercholesterolemia in the H. pylori-infected (N/%; 190/59.9%) and H. pylori-uninfected (N/%; 127/40%) participants (Table 3). A statistically significant difference (p < 0.001) was observed among the overall proportion of triglyceridemia in the H. pylori-infected (N/%; 136/68%) and H. pylori-uninfected (N/%; 64/32%) participants. The overall proportion of increased LDL-C and decreased HDL-C levels in the H. pylori-infected participants were (N/%; 234/53%) and (N/%; 149/71%), respectively (Table 3). On the other hand, the overall proportion of increased LDL-C and decreased HDL-C levels in the H. pylori-uninfected participants were (N/%; 201/46%) and (N/%; 60/28.7%), accordingly. A statistically significant difference (p < 0.01) was noticed in the proportions of an increased LDL-C as well as a decreased HDL-C of the H. pylori-infected and H. pylori-uninfected participants in the overall category of data (Table 3). The proportion (N/%) and p-value of all four components of dyslipidemia in the H. pylori-positive and -negative participants for the male, female, age < 30, age = 30–60, and age > 60 categories are summarized in detail in Table 3. The magnitude (number/proportion) of imbalance in the lipid profile (hypercholesterolemia, triglyceridemia, increased LDL levels, and decreased HDL levels) of males and females and ages < 30, ages > 30, age = 30–60, and ages > 60 are summarized in Table 3. The level of statistically significant differences (p-value) of the imbalance in lipid profiles in the H. pylori-positive and H. pylori-negative participants are also tabulated in Table 3 for the male, female, age < 30, age > 30, age = 30–60, and age > 60 categories.

3.4. H. pylori as an Associated Factor of Dyslipidemia among All (n = 510) Study Participants

H. pylori as an associated factor of dyslipidemia (hypercholesterolemia, hypertriglyceridemia, increased LDL-C levels, and decreased HDL-C levels) was assessed by measuring the crude odds ratio (COR) and adjusted odds ratio (AOR) by applying univariate and bivariate logistic regression statistical models. The p-value and 95% confidence interval (95%CI) were also evaluated for each odds ratio (Table 4). The COR and AOR for age, gender, cholesterol levels, triglyceride levels, LDL-C levels, and HDL-C levels were also obtained by univariate and multivariate logistic regressions to gain insight into H. pylori as the associated factor of imbalance in lipid profiles (Table 5). The odds of having hypercholesterolemia (AOR: 2.64, 95%CI: 1.824–3.848, p < 0.001), hypertriglyceridemia (AOR: 3.24, 95%CI: 2.227–4.757, p < 0.001), increased LDL-C levels (AOR: 2.174, 95%CI: 1.309–3.684, p < 0.01), and decreased HDL-C levels (AOR: 4.2, 95%CI: 2.937–6.321, p < 0.001) are 2.64, 3.24, 2.17, and 4. 2 times higher in H. pylori-infected individuals as compared with the H. pylori-uninfected individuals (Table 4). For a one-unit increase in cholesterol, the odds of being infected by H. pylori increases by 226.2% (AOR: 3.26, 95%CI: 1.778–6.258, p < 0.001) (Table 5). For a one-unit increase in the level of triglycerides, the odds of being infected by H. pylori increase by a factor of 1.3 (AOR: 1.298, 95%CI: 0.928–1.834, p > 0.05). For an increase of one unit in the concentration of HDL-C, the odds of being infected by H. pylori decrease by a factor of 89% (AOR: 0.11, 95%CI: 0.043–0.267, p < 0.11). Meanwhile, with a one-unit increase in the concentration of LDL-C, the odds of being infected by H. pylori decrease by 67% (AOR: 0.333, 95%CI: 0.156–0.676, p < 0.01) (Table 5). Though the AORs for the age and gender of the study participants were not statistically significant (p > 0.05), the males’ crude odds of being H. pylori-infected was 1.6 times higher in comparison to the female participants (COR: 1.581, 95%CI: 1.116–2.246, p < 0.05).

4. Discussion

This study was designed to gain an insight into the association of the H. pylori infection with an imbalance in any component of the lipid profile (dyslipidemia), such as cholesterol levels, triglyceride levels, LDL-C levels, and HDL-C levels among n = 510 study individuals. The number and proportion of hypercholesterolemia, triglyceridemia, increased LDL-C levels, and decreased HDL-C levels in H. pylori-infected individuals was measured to be 68% (N; 136), 59.9% (N; 190), 53% (N; 234), and 71% (N; 149), which is tabulated in Table 4. Our findings are corroborated with that of various other studies [15,21,25]. Moreover, a statistically significant difference (p < 0.001) was observed in the overall proportion of hypertriglyceridemia and hypercholesterolemia between the H. pylori-infected and -uninfected individuals. A statistically significant difference (p < 0.01) was noticed in the proportions of an increased LDL-C as well as a decreased HDL-C of the H. pylori-infected and H. pylori-uninfected participants in the overall category of the data (Table 3). A statistically significant association of dyslipidaemia with the H. pylori infection has been reported in various other scientific studies [38,39,40,41].
H. pylori as an associated factor of dyslipidaemia was assessed in terms of the crude odds ratio (COR) and adjusted odds ratio (AOR) by applying a logistic regression statistical model (Table 4). Our results demonstrate that the odds of having hypercholesterolemia (AOR: 2.64, 95%CI: 1.824–3.848, p < 0.001), hypertriglyceridemia (AOR: 3.24, 95%CI: 2.227–4.757, p < 0.001), increased LDL-C levels (AOR: 2.174, 95%CI: 1.309–3.684, p < 0.01), and decreased HDL-C levels (AOR: 4.2, 95%CI: 2.937–6.321, p < 0.001) are 2.64, 3.24, 2.17, and 4.2 times higher in H. pylori-infected individuals compared with H. pylori-uninfected individuals (Table 4). Shimamoto et al. described clinically and statistically significant positive associations of the infection with cholesterol levels (standardized mean difference/SDM; 0.09, 95%CI; 0.07–0.10), triglyceride levels (SDM; 0.06, 95%CI; 0.05–0.08), and LDL-C levels (SDM; 0.11, 95%CI; 0.09–0.12), while a negative association was observed with HDL-C levels (SDM; −0.13, 95%CI; −0.14 to −0.12) in a meta-analysis study which corroborates our finding [42]. The dyslipidemia determined in the present study is also consistent with the findings of Adachi et al., who demonstrated a lower concentration of cholesterol, triglycerides, and LDL-C and a higher level of HDL-C in successfully eradicated H. pylori study subjects as compared to the subjects with persistent H. pylori infections [43].
Our results of hypercholesterolemia were found to be in line with the results of Tali et al., who reported a statistically significant association of an enhanced total cholesterol (OR: 2.3324, p = 0.0002) with the H. pylori infection [39]. Tali et al. also reported a statistically significant association of increased LDL-C levels (OR: 2.3, p = 0.0006) with the H. pylori infection, which corroborates the findings of our study [39]. H. pylori-associated increased LDL-C levels were reported by Takashima et al. [44]. Takashima et al. also described the decreased HDL-C levels in H. pylori-infected patients [44]. A significant association of the H. pylori infection with enhanced LDL-C levels and decreased levels of HDL-C was reported by Kanbay et al., which is consistent with our findings [45]. In addition to this, in a study on the association of serologically positive H. pylori infections with alterations in the lipid profile, considering a relatively larger sample number (n = 2573), accomplished by Haeri et al., decreased HDL-C levels and increased LDL-C levels were reported to be significantly (p < 0.03) associated with the H. pylori infection [46].
A significant association of increased LDL-cholesterolemia levels and decreased HDL-cholesterolemia levels with the H. pylori infection in a Japanese male population was described in a study accomplished by Satoh et al. [40]. These findings, in terms of high LDL-cholesterolemia levels and low HDL-cholesterolemia levels, are of paramount importance, as both are major risk factors for atherosclerosis and coronary diseases [47].
In our study, we found that with a one-unit increase in the level of cholesterol, triglycerides, and LDL-C, the odds of being infected by H. pylori increases by 226.2% (AOR: 3.26, 95%CI: 1.778–6.258, p < 0.001), 30% (AOR: 1.298, 95%CI: 0.928–1.834, p > 0.05), and 67% (AOR: 0.333, 95%CI: 0.156–0.676, p < 0.01), respectively (Table 5). On the other hand, for an increase of one unit in the concentration of HDL-C, the odds of being infected by H. pylori decreases by a factor of 89% (AOR: 0.11, 95%CI: 0.043–0.267, p < 0.001) (Table 5). Our results corroborate those of an investigation (a cross-sectional study, n = 37,263) on the association of H. pylori colonization and infection with lipid profiles accomplished by Kim et al., who reported the statistically significant impact of the H. pylori infection on hypercholesterolemia (p  <  0.001), hyper-LDL-cholesterolemia (p  <  0.001), and hypo-HDL-cholesterolemia [38]. Dyslipidemia is recognized as one of the major risk factors for cardiovascular diseases (CVDs). Our results show H. pylori-infection-dependent alterations in the lipid profile of H. pylori-infected individuals, which suggests an increased risk of CVDs in H. pylori-infected subjects, which is substantiated by the findings of Sun et al., who reported an association of an increased risk of composite CVDs and coronary heart disease (CHD) with the H. pylori infection [18]. Sun et al. reported a slight association of CVDs (risk ratio/RR: 1.10) and CHD (risk ratio/RR: 1.10) [18]. Jamkhande et al. explained the direct or indirect impact of the H. pylori infection in the development of CVDs [48]. Sharma et al. described the role of the Cag-A-seropositive H. pylori strain as a predisposing factor of CVDs [49]. Furthermore, Torres et al. also described the indirect role of the H. pylori infection in the development of atherothrombosis and CVDs [50]. Though the AOR for the age and gender categories of the study participants were not statistically significant (p > 0.05), the males’ crude odds of being H. pylori-infected was 1.6 times higher in comparison to the female participants (COR: 1.581, 95%CI: 1.116–2.246, p < 0.05). However, there are various other studies, in which authors have reported results that are contradictory to our results and which demonstrate that H. pylori infection does not impact the lipid profile or interfere with lipid metabolism. Regnstrom et al. measured a statistically non-significant difference between the lipid profile and H. pylori seropositivity. Additionally, a significant association between the lipid profile (cholesterol and triglyceride levels) and the H. pylori infection was not reported by Patel et al. [51]. Vafaeimanesh et al. also did not observe any significant association of the lipid profile with the H. pylori infection in their study population [52]. Such discrepant findings could be explained by differences in the methods of diagnosis of the H. pylori infection, sample size, and variation in the study population.
The data for H. pylori detection was based only on rapid H. pylori antigen tests in the stool samples, which could be acknowledged as a limitation of the present study, and therefore, other methods of detection such as endoscopy, histopathological examinations of biopsies and the detection of genetic material in conjunction with serological tests (antigen and antibody) should be adopted to gain insights of the association between the H. pylori infection and dyslipidemia inquisitively. Although H. pylori-infected, severely ill patients who were kept on the long-term use of proton pump inhibitors (PPIs) were excluded from this study, the access to insufficient information on the short-term or intermittent use of PPIs by the study participants could be documented as a limitation of this study.

5. Conclusions

Our results demonstrate the enhanced risk of dyslipidemia in H. pylori-infected individuals compared to H. pylori-negative individuals. An increased risk of dyslipidemia is the major risk factor for cardiovascular and cerebrovascular disorders. The occurrence of dyslipidemia in H. pylori-infected individuals may trigger atherosclerosis, coronary heart disease, and cerebral infarction in the population. However, some reports do not elucidate the enhanced risk of dyslipidemia in H. pylori-infected individuals and that variation could be population-dependent; therefore, it is recommended to undertake such studies in different populations to achieve a full insight into this. Given the statistically significant association of dyslipidemia with H. pylori-positive individuals, the effective management of the lipid profile of H. pylori-infected patients would be beneficial to minimize the clinical impact of the infection on cardiovascular diseases. It would be interesting to accomplish a temporal assessment of the serum lipid profile concerning infections in H. pylori-infected patients to gain a deeper insight into the impact of the H. pylori infection on dyslipidemia.

Author Contributions

Conceptualization, M.A.I. and A.M.; data curation, M.A.I., O.A.A.M., E.A.A., M.A.A., J.A.A., A.R.A.G., A.M.A., D.M.M.D. and A.K.A.A.; formal analysis, M.A.I., O.A.A.M., A.M., A.R.A.G., A.M.A., D.M.M.D. and A.K.A.A.; investigation, M.A.I., O.A.A.M., A.M., E.A.A., M.A.A., J.A.A. and A.K.A.A.; methodology, M.A.I., O.A.A.M., A.M., E.A.A., M.A.A., J.A.A., A.R.A.G., A.M.A., D.M.M.D. and A.K.A.A.; project administration, M.A.I., E.A.A., M.A.A. and A.M.A.; resources, O.A.A.M., A.M., E.A.A., M.A.A., J.A.A., A.R.A.G., A.M.A., D.M.M.D. and A.K.A.A.; software, M.A.I., O.A.A.M., A.M., E.A.A., M.A.A., A.R.A.G., A.M.A., D.M.M.D. and A.K.A.A.; supervision, M.A.I., A.M. and J.A.A.; validation, M.A.I., O.A.A.M., A.M., E.A.A., M.A.A., J.A.A., A.R.A.G., D.M.M.D. and A.K.A.A.; visualization, M.A.I., O.A.A.M., E.A.A. and M.A.A.; writing—original draft, M.A.I.; writing—review and editing, M.A.I., O.A.A.M., A.M., E.A.A., M.A.A., J.A.A., A.R.A.G., A.M.A., D.M.M.D. and A.K.A.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was accomplished as per the guidelines of the Declaration of Helsinki. Ethical approval for this study was issued by the Research Ethical Committee (REC), Armed Forces Hospital southern region, Saudi Arabia, with reference number AFHSRMREC/2023/687 on 2 April 2023. The purpose of the collection of data was explained to the Committee, and informed consent was ensured before the commencement of this study. The REC ensures the confidentiality of patients and informed consent as regards the approved studies as per the REC policy of data protection and authorization.

Informed Consent Statement

Data confidentiality was maintained, and the purpose of the investigation was said to the Committee (in written consent) before the collection of data and the commencement of the research.

Data Availability Statement

The data supporting these research findings are not publicly available to protect the privacy of the research participants. However, they are available from the corresponding author.

Acknowledgments

This study was supported by the Armed Forces Hospital of the southern region of Saudi Arabia for the availability of their data. Our study was also supported by the Bioinformatics and Communication Laboratory of the Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Al-Baha, University, KSA.

Conflicts of Interest

The authors declare that there are no conflict of interest.

References

  1. Goodwin, C. Helicobacter pylori: 10th anniversary of its culture in April 1982. Gut 1993, 34, 293. [Google Scholar] [CrossRef] [PubMed]
  2. Gravina, A.; Zagari, R.; De Musis, C.; Romano, L.; Loguercio, C.; Romano, M. Helicobacter pylori y enfermedades extragástricas: Una revisión. Rev. Mund. Gastroenterol. 2018, 24, 32–44. [Google Scholar]
  3. Hooi, J.K.; Lai, W.Y.; Ng, W.K.; Suen, M.M.; Underwood, F.E.; Tanyingoh, D.; Malfertheiner, P.; Graham, D.Y.; Wong, V.W.; Wu, J.C. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology 2017, 153, 420–429. [Google Scholar] [CrossRef]
  4. Alkharsah, K.R.; Aljindan, R.Y.; Alamri, A.M.; Alomar, A.I.; Al-Quorain, A.A. Molecular characterization of Helicobacter pylori clinical isolates from Eastern Saudi Arabia. Saudi Med. J. 2022, 43, 1128–1135. [Google Scholar] [CrossRef] [PubMed]
  5. Alghamdi, T.S.; Ansari, T.; Bashir, A.A.; Batais, M.A.; Aldhahi, M.F.; Alanazi, M.A. Helicobacter pylori infection among dyspepsia patients in suburbs of Riyadh, Saudi Arabia. J. Pak. Med. Assoc. 2020, 70, 2174–2177. [Google Scholar]
  6. Al-Akwaa, A.M. Prevalence of Helicobacter pylori infection in a group of morbidly obese Saudi patients undergoing bariatric surgery: A preliminary report. Saudi J. Gastroenterol. 2010, 16, 264. [Google Scholar] [CrossRef] [PubMed]
  7. Khoder, G.; Muhammad, J.S.; Mahmoud, I.; Soliman, S.S.; Burucoa, C. Prevalence of Helicobacter pylori and its associated factors among healthy asymptomatic residents in the United Arab Emirates. Pathogens 2019, 8, 44. [Google Scholar] [CrossRef] [PubMed]
  8. Cover, T.L.; Blaser, M.J. Helicobacter pylori in health and disease. Gastroenterology 2009, 136, 1863–1873. [Google Scholar] [CrossRef] [PubMed]
  9. Blaser, M.J. Hypothesis: The changing relationships of Helicobacter pylori and humans: Implications for health and disease. J. Infect. Dis. 1999, 179, 1523–1530. [Google Scholar] [CrossRef]
  10. Romano, M.; Ricci, V.; Zarrilli, R. Mechanisms of disease: Helicobacter pylori-related gastric carcinogenesis—Implications for chemoprevention. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006, 3, 622–632. [Google Scholar] [CrossRef]
  11. Censini, S.; Stein, M.; Covacci, A. Cellular responses induced after contact with Helicobacter pylori. Curr. Opin. Microbiol. 2001, 4, 41–46. [Google Scholar] [CrossRef] [PubMed]
  12. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Acrylamide. In Some Industrial Chemicals; International Agency for Research on Cancer: Lyon, France, 1994. [Google Scholar]
  13. Blecker, U.; Renders, F.; Lanciers, S.; Vandenplas, Y. Syncopes leading to the diagnosis of a Helicobacter pylori positive chronic active haemorrhagic gastritis. Eur. J. Pediatr. 1991, 150, 560–561. [Google Scholar] [CrossRef] [PubMed]
  14. Campuzano-Maya, G. Hematologic manifestations of Helicobacter pylori infection. World J. Gastroenterol. WJG 2014, 20, 12818. [Google Scholar] [CrossRef] [PubMed]
  15. Hashim, M.; Mohammed, O.; Wolde, M. The association of Helicobacter pylori infection with dyslipidaemia and other atherogenic factors in dyspeptic patients at St. Paul’s Hospital Millennium Medical College. Heliyon 2022, 8, e09430. [Google Scholar] [CrossRef] [PubMed]
  16. Ozdogru, I.; Kalay, N.; Dogan, A.; Inanc, M.T.; Kaya, M.G.; Topsakal, R.; Gul, I.; Kutukoglu, I.; Kilic, H.; Eryol, N.K. The relationship between Helicobacter pylori IgG titre and coronary. Acta Cardiol. 2007, 62, 501–505. [Google Scholar] [CrossRef]
  17. Laek, B.; Szklo, M.; McClelland, R.L.; Ding, J.; Tsai, M.Y.; Bluemke, D.A.; Tracy, R.; Matsushita, K. The prospective association of Chlamydia pneumoniae and four other pathogens with development of coronary artery calcium: The multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2013, 230, 268–274. [Google Scholar] [CrossRef]
  18. Sun, L.; Zheng, H.; Qiu, M.; Hao, S.; Liu, X.; Zhu, X.; Cai, X.; Huang, Y. Helicobacter pylori infection and risk of cardiovascular disease. Helicobacter 2023, 28, e12967. [Google Scholar] [CrossRef]
  19. Gillum, R.F. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: The Third National Health and Nutrition Examination Survey. J. Natl. Med. Assoc. 2004, 96, 1470. [Google Scholar]
  20. Sotiropoulos, A.; Gikas, A.; Skourtis, S.; Merkouris, P.; Pentzeridis, P.; Polydorou, A.; Pappas, S. Seropositivity to Chlamydia pneumoniae or Helicobacter pylori and coronary artery disease. Int. J. Cardiol. 2006, 109, 420–421. [Google Scholar] [CrossRef]
  21. Park, Y.; Kim, T.J.; Lee, H.; Yoo, H.; Sohn, I.; Min, Y.W.; Min, B.H.; Lee, J.H.; Rhee, P.L.; Kim, J.J. Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study. Helicobacter 2021, 26, e12783. [Google Scholar] [CrossRef]
  22. Abdu, A.; Cheneke, W.; Adem, M.; Belete, R.; Getachew, A. Dyslipidemia and associated factors among patients suspected to have Helicobacter pylori infection at Jimma University Medical Center, Jimma, Ethiopia. Int. J. Gen. Med. 2020, 13, 311–321. [Google Scholar] [CrossRef]
  23. Nigatie, M.; Melak, T.; Asmelash, D.; Worede, A. Dyslipidemia and Its Associated Factors among Helicobacter pylori-Infected Patients Attending at University of Gondar Comprehensive Specialized Hospital, Gondar, North-West Ethiopia: A Comparative Cross-Sectional Study. J. Multidiscip. Healthc. 2022, 15, 1481–1491. [Google Scholar] [CrossRef] [PubMed]
  24. Pappan, N.; Rehman, A. Dyslipidemia. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2022. [Google Scholar]
  25. Karim, I.; Zardari, A.K.; Shaikh, M.K.; Baloch, Z.A.Q.; Shah, S.Z.A. Dyslipidemia; helicobacter pylori infected patients. Prof. Med. J. 2014, 21, 956–959. [Google Scholar]
  26. Kopin, L.; Lowenstein, C.J. Dyslipidemia. Ann. Intern. Med. 2017, 167, ITC81–ITC96. [Google Scholar] [CrossRef]
  27. Welty, F.K. Hypobetalipoproteinemia and abetalipoproteinemia. Curr. Opin. Lipidol. 2014, 25, 161. [Google Scholar] [CrossRef]
  28. Arsenault, B.J.; Rana, J.S.; Stroes, E.S.; Després, J.-P.; Shah, P.K.; Kastelein, J.J.; Wareham, N.J.; Boekholdt, S.M.; Khaw, K.-T. Beyond low-density lipoprotein cholesterol: Respective contributions of non–high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J. Am. Coll. Cardiol. 2009, 55, 35–41. [Google Scholar]
  29. Purva, A.; Sharma, K.; Khan, M.S. A review on dyslipidemia: Types, risk factors and management. Asian J. Pharm. Res. Dev. 2020, 8, 96–98. [Google Scholar] [CrossRef]
  30. Musunuru, K. Atherogenic dyslipidemia: Cardiovascular risk and dietary intervention. Lipids 2010, 45, 907–914. [Google Scholar] [CrossRef] [PubMed]
  31. Khera, A.V.; Demler, O.V.; Adelman, S.J.; Collins, H.L.; Glynn, R.J.; Ridker, P.M.; Rader, D.J.; Mora, S. Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events: An analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation 2017, 135, 2494–2504. [Google Scholar] [CrossRef]
  32. Khovidhunkit, W.; Kim, M.S.; Memon, R.A.; Shigenaga, J.K.; Moser, A.H.; Feingold, K.R.; Grunfeld, C. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J. Lipid Res. 2004, 45, 1169–1196. [Google Scholar] [CrossRef]
  33. Kusters, J.G.; Van Vliet, A.H.; Kuipers, E.J. Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev. 2006, 19, 449–490. [Google Scholar] [CrossRef]
  34. Yamane, T. Statistics an Industry Analysis, 2nd ed.; Harper & Row: New York, NY, USA, 1967. [Google Scholar]
  35. Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.-C.; James, W.P.T.; Loria, C.M.; Smith Jr, S.C. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009, 120, 1640–1645. [Google Scholar]
  36. Bush, V.; Smola, C.; Schmitt, P. Evaluation of the Beckman Coulter DxC 700 AU chemistry analyzer. Pract. Lab. Med. 2020, 18, e00148. [Google Scholar] [CrossRef]
  37. Shimoyama, T. Stool antigen tests for the management of Helicobacter pylori infection. World J. Gastroenterol. 2013, 19, 8188–8191. [Google Scholar] [CrossRef]
  38. Kim, H.L.; Jeon, H.H.; Park, I.Y.; Choi, J.M.; Kang, J.S.; Min, K.W. Helicobacter pylori infection is associated with elevated low density lipoprotein cholesterol levels in elderly Koreans. J. Korean Med. Sci. 2011, 26, 654–658. [Google Scholar] [CrossRef] [PubMed]
  39. Tali, L.D.N.; Faujo, G.F.N.; Konang, J.L.N.; Dzoyem, J.P.; Kouitcheu, L.B.M. Relationship between active Helicobacter pylori infection and risk factors of cardiovascular diseases, a cross-sectional hospital-based study in a Sub-Saharan setting. BMC Infect. Dis. 2022, 22, 731. [Google Scholar] [CrossRef]
  40. Satoh, H.; Saijo, Y.; Yoshioka, E.; Tsutsui, H. Helicobacter Pylori infection is a significant risk for modified lipid profile in Japanese male subjects. J. Atheroscler. Thromb. 2010, 17, 1041–1048. [Google Scholar] [CrossRef] [PubMed]
  41. Kucukazman, M.; Yavuz, B.; Sacikara, M.; Asilturk, Z.; Ata, N.; Ertugrul, D.T.; Yalcin, A.A.; Yenigun, E.C.; Kizilca, G.; Okten, H.; et al. The relationship between updated Sydney System score and LDL cholesterol levels in patients infected with Helicobacter pylori. Dig. Dis. Sci. 2009, 54, 604–607. [Google Scholar] [CrossRef] [PubMed]
  42. Shimamoto, T.; Yamamichi, N.; Gondo, K.; Takahashi, Y.; Takeuchi, C.; Wada, R.; Mitsushima, T.; Koike, K. The association of Helicobacter pylori infection with serum lipid profiles: An evaluation based on a combination of meta-analysis and a propensity score-based observational approach. PLoS ONE 2020, 15, e0234433. [Google Scholar] [CrossRef]
  43. Adachi, K.; Mishiro, T.; Toda, T.; Kano, N.; Fujihara, H.; Mishima, Y.; Konishi, A.; Mochida, M.; Takahashi, K.; Kinoshita, Y. Effects of Helicobacter pylori eradication on serum lipid levels. J. Clin. Biochem. Nutr. 2018, 62, 264–269. [Google Scholar] [CrossRef] [PubMed]
  44. Takashima, T.; Adachi, K.; Kawamura, A.; Yuki, M.; Fujishiro, H.; Rumi, M.A.; Ishihara, S.; Watanabe, M.; Kinoshita, Y. Cardiovascular risk factors in subjects with Helicobacter pylori infection. Helicobacter 2002, 7, 86–90. [Google Scholar] [CrossRef] [PubMed]
  45. Kanbay, M.; Gür, G.; Yücel, M.; Yilmaz, U.; Boyacioğlu, S. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig. Dis. Sci. 2005, 50, 1228–1231. [Google Scholar] [CrossRef] [PubMed]
  46. Haeri, M.; Parham, M.; Habibi, N.; Vafaeimanesh, J. Effect of Helicobacter pylori Infection on Serum Lipid Profile. J. Lipids 2018, 2018, 6734809. [Google Scholar] [CrossRef] [PubMed]
  47. Mahmood, S.S.; Levy, D.; Vasan, R.S.; Wang, T.J. The Framingham Heart Study and the epidemiology of cardiovascular disease: A historical perspective. Lancet 2014, 383, 999–1008. [Google Scholar] [CrossRef]
  48. Jamkhande, P.G.; Gattani, S.G.; Farhat, S.A. Helicobacter pylori and cardiovascular complications: A mechanism based review on role of Helicobacter pylori in cardiovascular diseases. Integr. Med. Res. 2016, 5, 244–249. [Google Scholar] [CrossRef] [PubMed]
  49. Sharma, V.; Aggarwal, A. Helicobacter pylori: Does it add to risk of coronary artery disease. World J. Cardiol. 2015, 7, 19. [Google Scholar] [CrossRef]
  50. Torres, A.M.; Gaensly, M.M. Helicobacter pylori: A new cardiovascular risk factor? Rev. Esp. Cardiol. 2002, 55, 652–656. [Google Scholar] [CrossRef]
  51. Patel, P.; Mendall, M.A.; Carrington, D.; Strachan, D.P.; Leatham, E.; Molineaux, N.; Levy, J.; Blakeston, C.; Seymour, C.A.; Camm, A.J.; et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995, 311, 711–714. [Google Scholar] [CrossRef]
  52. Vafaeimanesh, J.; Hejazi, S.F.; Damanpak, V.; Vahedian, M.; Sattari, M.; Seyyedmajidi, M. Association of Helicobacter pylori infection with coronary artery disease: Is Helicobacter pylori a risk factor? Sci. World J. 2014, 2014, 516354. [Google Scholar] [CrossRef]
Life 13 02206 g001
Figure 1. Illustration of a concept map of the method: sample size, study parameters, analysis techniques, and data visualization resources.
Figure 1. Illustration of a concept map of the method: sample size, study parameters, analysis techniques, and data visualization resources.
Life 13 02206 g001
Life 13 02206 g002
Figure 2. Illustration of lipid profile by H. pylori-infection status: (a) cholesterol disaggregated by infection status, (b) level of triglycerides by H. pylori-infection status, (c) LDL cholesterol by infection status, and (d) HDL cholesterol by status of H. pylori infection.
Figure 2. Illustration of lipid profile by H. pylori-infection status: (a) cholesterol disaggregated by infection status, (b) level of triglycerides by H. pylori-infection status, (c) LDL cholesterol by infection status, and (d) HDL cholesterol by status of H. pylori infection.
Life 13 02206 g002
Life 13 02206 g003
Figure 3. Correlogram of lipid profile by H. pylori-infection status: correlation coefficients (r) depicted in grey, red, and cyan colors represent the correlation between the parameter of the lipid profile in the overall, H. pylori−negative and H. pylori−positive individuals, respectively. Then number of asterisk defines the level of statistical significance.
Figure 3. Correlogram of lipid profile by H. pylori-infection status: correlation coefficients (r) depicted in grey, red, and cyan colors represent the correlation between the parameter of the lipid profile in the overall, H. pylori−negative and H. pylori−positive individuals, respectively. Then number of asterisk defines the level of statistical significance.
Life 13 02206 g003
Table 1. Tabulation of baseline characteristics of all the participants (n = 510) stratified into six categories.
Table 1. Tabulation of baseline characteristics of all the participants (n = 510) stratified into six categories.
VariablesStatisticsCategories
OverallMaleFemaleAge < 30 (In Years)Age = 30–60 (In Years)Age > 60 (In Years)
Age (In years)MEDIAN (IQR)43.0 (53.0–35.0)42.0 (52.0–33.0)45.0 (54.0–36.0)24.0 (27.0–19.0)44.00 (51.00–37.00) 66.0 (70.00–63.0)
Mean ± SD44.01 ± 13.5843.31 ± 13.8144.69 ± 13.3323.01 ± 5.4544.01 ± 8.1067.29 ± 5.83
Cholesterol (mmol/L)MEDIAN (IQR)5.34(5.83–4.75)5.37 (5.83–4.85) 5.30 (5.84–4.71)4.71 n(5.36–4.21)5.39 (5.90–4.92)5.43 (5.89–5.01)
Mean ± SD5.36 ± 0.965.38 ± 1.025.34 ± 0.924.78 ± 0.895.47 ± 0.935.38 ± 1.05
Triglyceride (mmol/L)MEDIAN (IQR)1.35(1.89–0.91)1.60 (1.98– 1.04)1.20 (1.79–0.86)0.99 (1.73–0.70)1.36 (1.91–0.94)1.65 (1.92–1.08)
Mean ± SD1.49 ± 0.721.60 ± 0.741.37 ± 0.681.18 ± 0.651.52 ± 0.731.20 ± 0.66
HDL (mmol/L)MEDIAN (IQR)1.22 (1.39–1.02)1.09 (1.26–0.93)1.31 (1.50–1.16)1.21 (1.49–1.07)1.22 (1.39–1.04)1.23 (1.37–0.95)
Mean ± SD1.23 ± 0.291.11 ± 0.261.35 ± 0.271.27 ± 0.311.23 ± 0.281.20 ± 0.31
LDL (mmol/L)MEDIAN(IQR)3.33 (3.76–2.78)3.38 (3.90–2.87)3.24 (3.74–2.74)2.76 (3.16–2.27)3.41 (3.89–2.92)3.35 (3.76–2.79)
Mean ± SD3.35 ± 0.78 3.43 ± 0.843.27 ± 0.712.82 ± 0.663.45 ± 0.773.35 ± 0.79
ALT.U/LMEDIAN (IQR)20.0 (28.0–14.25)25.0(35.0–20.0)16.0 (21.0–12.0)16.0 (27.75–11.00)21.0 (30.0–16.0)19.0 (22.0–15.0)
Mean ± SD24.16 ± 16.5831.11 ± 19.9917.38 ± 7.7722.11± 20.4925.21 ± 16.6020.19 ± 9.51
AST.U/LMEDIAN (IQR)22.0 (27.0–18.0)24.0 (29.0–22.0)20.0 (24.0–16.25)20.0 (27.0–17.25)22.0 (27.0–18.0)23.0 (25.50–19.0)
Mean ± SD23.9 ±8.6826.66 ± 9.3621.19 ± 6.9722.53 ± 7.4124.29 ± 9.1323.06 ± 6.90
ALP.ULMEDIAN (IQR)68.0 (82.75–57.0)70.0 (87.0–60.75)66.0 (81.0–53.0)74.0 (94.25–59.50)67.00 (81.0–57.0)68.0 (80.50–58.50)
Mean ± SD74.84 ± 35.0778.44± 35.6671.32 ± 34.2091.79 ± 63.5271.49 ± 21.1576.02 ± 50.02
HbA1c (%)MEDIAN(IQR)5.5(5.8–5.1)5.5 (5.8–5.1)5.5 (5.88–5.2)5.20 (5.48–5.0)5.5 (5.8–5.2)6.00 (6.70–5.50)
Mean ± SD5.77 ± 2.94 5.87 ± 4.095.68 ± 0.865.24 ± 0.285.76 ± 3.366.44 ± 1.32
ALP = Alkaline phosphatase, SD = standard deviation, Hb = hemoglobin, IQR = interquartile range, AST = aspartate aminotransferase, ALT = alanine aminotransferase.
Table 2. Comparative status of lipid profile by Helicobacter pylori-infection status (by applying Welch’s two sample t-test and the SD function).
Table 2. Comparative status of lipid profile by Helicobacter pylori-infection status (by applying Welch’s two sample t-test and the SD function).
Overall Participants (n = 510)
Lipid ProfileHelicobacter pylori-Infection Statusp-Value
H. pylori Negative (n = 250)H. pylori Positive (n = 260)
Mean ± SDMean ± SD
Cholesterol (mmol/L)5.22 ± 1.05.49 ± 0.85p < 0.01
Triglyceride (mmol/L)1.29 ± 0.621.66 ± 0.75p < 0.001
LDL-C (mmol/L)3.26 ± 0.813.43 ± 0.74p < 0.05
HDL-C (mmol/L)1.30 ± 0.251.15 ± 0.30p < 0.001
Male participants (n = 252)
H. pylori negative (n = 109)H. pylori positive (n = 143)p-value
Cholesterol (mmol/L)5.19 ± 1.025.53 ± 0.85p < 0.05
Triglycerides (mmol/L)1.43 ± 0.671.73 ± 0.75p < 0.01
LDL-C (mmol/L)3.32 ± 0.903.51 ± 0.78p > 0.05
HDL-C (mmol/L)1.18 ± 0.211.05 ± 0.28p < 0.001
Female participants (n = 258)
H. pylori negative (n = 141)H. pylori positive (n = 117)p-value
Cholesterol (mmol/L)5.24 ± 0.945.45 ± 0.86p > 0.05
Triglycerides (mmol/L)1.19 ± 0.571.58 ± 0.74p < 0.001
LDL-C (mmol/L)3.21 ± 0.733.33 ± 0.67p > 0.05
HDL-C (mmol/L)1.40 ± 0.241.27 ± 0.27p < 0.001
Age category (Age < 30, n = 70)
H. pylori negative (n = 40)H. pylori positive (n = 30)p-value
Cholesterol (mmol/L)4.49 ± 0.915.16 ± 0.69p < 0.001
Triglyceride (mmol/L)0.88 ± 0.421.56 ± 0.70p < 0.001
LDL-C (mmol/L)2.68 ± 0.673.00 ± 0.58p < 0.05
HDL-C (mmol/L)1.35 ± 0.261.15 ± 0.33p < 0.01
Age category (Age = 30–60, n = 377)
H. pylori negative (n = 180)H. pylori positive (n = 197)p-value
Cholesterol (mmol/L)5.39 ± 1.05.53 ± 0.83p > 0.05
Triglycerides (mmol/L)1.36 ± 0.631.66 ± 0.78p < 0.001
LDL-C (mmol/L)3.40 ± 0.793.48 ± 0.74p > 0.05
HDL-C (mmol/L)1.29 ± 0.241.17 ± 0.29p < 0.001
Age category (Age > 60, n = 63)
H. pylori negative (n = 30)H. pylori positive (n = 33)p-value
Cholesterol (mmol/L)5.17 ± 0.995.57 ± 1.01p > 0.05
Triglycerides (mmol/L)1.46 ± 0.641.75 ± 0.64p > 0.05
LDL-C (mmol/L)3.17 ± 0.773.50 ± 0.79p > 0.05
HDL-C (mmol/L)1.33 ± 0.2791.06 ± 0.28p < 0.001
Table 3. The magnitude of dyslipidemia among the H. pylori-infected and -uninfected study participants in the Asir region of Saudi Arabia (2-sample test for equality of proportions and Pearson’s Chi-squared test to assess p-values).
Table 3. The magnitude of dyslipidemia among the H. pylori-infected and -uninfected study participants in the Asir region of Saudi Arabia (2-sample test for equality of proportions and Pearson’s Chi-squared test to assess p-values).
Overall Participants
DyslipidemiaHelicobacter pylori-Infection Statusp-Value
H. pylori NegativeH. pylori Positive
N (%)N (%)
Hypercholesterolemia127 (40%)190 (59.9%)p < 0.001
Hypertriglyceridemia64 (32%)136 (68%)p < 0.001
Increased LDL-C201 (46%)234 (53%)p < 0.01
Decreased HDL-C60 (28.7%)149 (71%)p < 0.001
Male participants
Hypercholesterolemia56 (33.5%)111 (66.4%)p < 0.001
Hypertriglyceridemia36 (30.7%)81 (69.2%)p < 0.001
Increased LDL-C88 (40%)131 (59.8%)p < 0.05
Decreased HDL-C14 (16%)73 (83.9%)p < 0.001
Female participants
Hypercholesterolemia71 (47.3%)79 (52.6%)p < 0.01
Hypertriglyceridemia28 (33.7%)55 (66.2%)p < 0.001
Increased LDL-C113 (52.3%)103 (47.6%)p > 0.05
Decreased HDL-C46 (37.7%)76 (62.2%)p < 0.001
Age category (Age < 30)
Hypercholesterolemia7 (25%)21 (75%)p < 0.001
Hypertriglyceridemia3 (10.5%)16 (84.2%)p < 0.001
Increased LDL-C22 (48%)23 (51.1%)p > 0.05
Decreased HDL-C8 (36.3%)14 (63.6%)p < 0.05
Age category (Age = 30–60)
Hypercholesterolemia104 (42.1%)143 (57.8%)p < 0.01
Hypertriglyceridemia50 (33.1%)101 (66.8%)p < 0.001
Increased LDL-C156 (46.1%)182 (53.8%)p > 0.05
Decreased HDL-C44 (28.3%)111 (71.6%)p < 0.001
Age category (Age > 60)
Hypercholesterolemia16 (38%)26 (61.9%)p > 0.05
Hypertriglyceridemia11 (36.6%)19 (63.3%)p > 0.05
Increased LDL-C23 (44.2%)29 (55.7%)p > 0.05
Decreased HDL-C8 (25%)24 (75%)p < 0.001
Table 4. Univariate and bivariate logistic regression analyses for assessing H. pylori-associated dyslipidemia.
Table 4. Univariate and bivariate logistic regression analyses for assessing H. pylori-associated dyslipidemia.
Dyslipidemia by H. pylori InfectionUnivariate BLRBivariate BLR
Unadjusted OR/CORAdjusted OR (AOR)
CORp-ValueAORp-Value
Hypercholesterolemia2.629p < 0.0012.641p < 0.001
Triglyceridemia3.187p < 0.0013.241p < 0.001
Increased LDL-C2.194p < 0.012.174p < 0.01
Decreased HDL-C4.251p < 0.0014.287p < 0.001
BLR = binary logistic regression; COR = crude odds ratio; OR = odds ratio; AOR = adjusted odds ratio, adjusted for age and HbA1c of all the participants; reference/dummy category = H. pylori-negative participants.
Table 5. Univariate and multivariate logistic regression analyses for determining the association of H. pylori infection with age, gender, and all four parameters of the lipid profile.
Table 5. Univariate and multivariate logistic regression analyses for determining the association of H. pylori infection with age, gender, and all four parameters of the lipid profile.
Demographic and Lipid Profile by H. pylori InfectionUnivariate BLRMultivariate BLR
Unadjusted OR/CORAdjusted OR (AOR)
CORp-ValueAORp-Value
Age (in years)1.003p > 0.050.994p > 0.05
Gender1.581p < 0.051.060p > 0.05
Cholesterol (mmol/L)1.357p < 0.013.262p < 0.001
Triglyceride (mmol/L)2.195p < 0.0011.298p > 0.05
LDL-C (mmol/L)1.314p < 0.050.333p < 0.01
HDL-C (mmol/L)0.143p < 0.0010.110p < 0.001
BLR = binary logistic regression; COR = crude odds ratio; OR = odds ratio; AOR = adjusted odds ratio, adjusted for all 5 parameters except for the ones for which the odds ratio has been described in the table. The reference category for gender was female. The reference category for the outcome variable was H. pylori-uninfected individuals.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Izhari, M.A.; Al Mutawa, O.A.; Mahzari, A.; Alotaibi, E.A.; Almashary, M.A.; Alshahrani, J.A.; Gosady, A.R.A.; Almutairi, A.M.; Dardari, D.M.M.; AlGarni, A.K.A. Helicobacter pylori (H. pylori) Infection-Associated Dyslipidemia in the Asir Region of Saudi Arabia. Life 2023, 13, 2206. https://doi.org/10.3390/life13112206

AMA Style

Izhari MA, Al Mutawa OA, Mahzari A, Alotaibi EA, Almashary MA, Alshahrani JA, Gosady ARA, Almutairi AM, Dardari DMM, AlGarni AKA. Helicobacter pylori (H. pylori) Infection-Associated Dyslipidemia in the Asir Region of Saudi Arabia. Life. 2023; 13(11):2206. https://doi.org/10.3390/life13112206

Chicago/Turabian Style

Izhari, Mohammad Asrar, Omar A. Al Mutawa, Ali Mahzari, Essa Ajmi Alotaibi, Maher A. Almashary, Jaber Abdullah Alshahrani, Ahmed R. A. Gosady, Abdulrahman M Almutairi, Daifallah M. M. Dardari, and Abdul Kareem A. AlGarni. 2023. "Helicobacter pylori (H. pylori) Infection-Associated Dyslipidemia in the Asir Region of Saudi Arabia" Life 13, no. 11: 2206. https://doi.org/10.3390/life13112206

APA Style

Izhari, M. A., Al Mutawa, O. A., Mahzari, A., Alotaibi, E. A., Almashary, M. A., Alshahrani, J. A., Gosady, A. R. A., Almutairi, A. M., Dardari, D. M. M., & AlGarni, A. K. A. (2023). Helicobacter pylori (H. pylori) Infection-Associated Dyslipidemia in the Asir Region of Saudi Arabia. Life, 13(11), 2206. https://doi.org/10.3390/life13112206

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop